Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVA322 in Moderate-to-Severe Plaque Psoriasis
NCT02243787Phase 2Terminated
- Sponsor
- Covagen AG
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of COVA322 in plaque psoriasis, sponsored by Covagen AG. Started Apr 2014; status: terminated.
02
Drugs
COVA322
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02243787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243787.